During carcinogenesis, TGF-β acts as a tumour suppressor, by inhibiting tumour cell replication and favouring apoptosis [33, 34], while at later stages of tumour progression it exerts protumourigenic effects that include tumour survival, induction of epithelial-mesenchymal transition (EMT), enhanced tumour invasion, and immunosuppressive and proangiogenic activities [32–34]. Here, TGFB1 is linked to neoplasm.